clinical trials

While decentralized trails seem like a win-win-win, one of the biggest concerns surrounding this model is the safety and integrity of the drug when it is shipped to the patient’s home. This direct-to-patient model relies on a robust logistics strategy to support product viability and security.

Express firm adds 17 origin markets in Mexico for samples deliveries to U.S. labs.